CGAS and neoplasm: PARPi therapy leads to the accumulation of cytoplasmic DNA, which activates the cGAS/STING pathway, thereby creating an influx of natural killer (NK) cells, T-lymphocytes, and tumor-infiltrating lymphocytes (TIL) within the TME [34,35].